Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danielle Hansen

Geriatric Medicine Erie, PA Doctor of Osteopathy

NPI 1548436389 CMS profile 252152

5535 Peach St Fl 1, Erie, PA 16509

Open in the dashboard

General payments

$5,375

317 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Hansen of Erie, PA is reported in the CMS Open Payments database as having received $5,375 across 317 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $543 20
2024 General $1,141 44
2023 General $1,308 95
2022 General $1,351 97
2021 General $414 26
2020 General $78 5
2019 General $539 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Hansen
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Danielle Hansen were reported at $543. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Danielle Hansen Geriatric Medicine median Middle half National median
2019 $539 $122 $40–$435 $163
2020 $78 $98 $25–$349 $114
2021 $414 $125 $34–$441 $132
2022 $1,351 $124 $36–$408 $149
2023 $1,308 $121 $41–$383 $160
2024 $1,141 $134 $41–$435 $164
2025 $543 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,097 115 payments
  2. Lilly USA, LLC $657 35 payments
  3. Teva Pharmaceuticals USA, Inc. $314 12 payments
  4. Pfizer Inc. $254 16 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $238 16 payments
  6. Baxter Healthcare $196 2 payments
  7. Amgen Inc. $163 8 payments
  8. Eisai Inc. $157 8 payments
  9. Merck Sharp & Dohme Corporation $155 8 payments
  10. Galderma Laboratories, L.P. $148 1 payment
  11. Other $1,997 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,123 315 payments
  2. Travel and Lodging $150 1 payment
  3. Education $102 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $968 107 payments
  2. RYBELSUS $834 105 payments
  3. JARDIANCE $215 15 payments
  4. MOUNJARO $199 9 payments
  5. Hillrom - Centrella Smart+ Bed $196 2 payments
  6. EMGALITY $161 9 payments
  7. STEGLATRO $155 8 payments
  8. TRADJENTA $154 11 payments
  9. AKLIEF $148 1 payment
  10. Austedo XR $146 8 payments
  11. Other $4,245 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 174 drugs

Part D claims

10,868

Median for Geriatric Medicine: 2,306

Drug cost

$694,313

Median for Geriatric Medicine: $150,713

Branded share of claims

19.2%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 172 $106,383
Eliquis Apixaban Brand 108 $82,160
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 91 $64,437
Tradjenta Linagliptin Brand 42 $39,001
Trulicity Dulaglutide Brand 25 $26,441
Jardiance Empagliflozin Brand 31 $21,982
Myrbetriq Mirabegron Brand 33 $17,612
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 35 $17,052
Rexulti Brexpiprazole Brand 17 $16,406
Atorvastatin Calcium Generic 793 $11,683

The 10 drugs with the highest cost, of 174 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$79,962

Medicare's payments for the services billed

Medicare patients

244

Average age 76

Services billed

2,143

172 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Depression 45%
Diabetes 36%
Alzheimer's or dementia 33%
Ischemic heart disease 26%
Heart failure 25%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AKLIEF
  • Galderma Laboratories, L.P. $148
$148 — —
Leqembi
  • Eisai Inc. $97
$97 — —
ZEPBOUND
  • Lilly USA, LLC $91
$91 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $75
$75 — —
Wegovy
  • Novo Nordisk Inc $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record